Page 370 - Read Online

Rizzieri et al. J Cancer Metastasis Treat 2019;5:26 I http://dx.doi.org/10.20517/2394-4722.2019.05 Page 13 of 16

long-term study. World J Surg Oncol 2014;12:234.
5. Chawla SS, Kumar SK, Dispenzieri A, Greenberg AJ, Larson DR, et al. Clinical course and prognosis of non-secretory multiple myeloma.
Eur J Haematol 2015; doi: 10.1111/ejh.12534.
6. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N. International myeloma working group molecular classification of multiple
myeloma: spotlight review. Leukemia 2009;23:2210-21.
7. Preston DL, Kusumi S, Tomonaga M, Izumi S, Ron E, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and
multiple myeloma, 1950-1987. Radiat Res 1994;137:S68-97.
8. Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS)
and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006;107:904-6.
9. Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, et al. Racial disparities in incidence and outcome in multiple myeloma: a
population-based study. Blood 2010;116:5501-6.
10. Verma PS, Howard RS, Weiss BM. The impact of race on outcomes of autologous transplantation in patients with multiple myeloma. Am J
Hematol 2008;83:355-8.
11. Larsson SC, Wolk A. Body mass index and risk of multiple myeloma: a meta-analysis. Int J Cancer 2007;121:2512-6.
12. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, et al. Body fatness and cancer - viewpoint of the IARC Working Group.
N Engl J Med 2016;375:794-8.
13. Wallin A, Larsson SC. Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies. Eur J Cancer
2011;47:1606-15.
14. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis
of prospective observational studies. Lancet 2008;371:569-78.
15. Teras LR, Kitahara CM, Birmann BM, Hartge PA, Wang SS, et al. Body size and multiple myeloma mortality: a pooled analysis of 20
prospective studies. Br J Haematol 2014;166:667-76.
16. Chiu BC, Gapstur SM, Greenland P, Wang R, Dyer A. Body mass index, abnormal glucose metabolism, and mortality from hematopoietic
cancer. Cancer Epidemiol Biomarkers Prev 2006;15:2348-54.
17. Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden CL. Trends in obesity and severe obesity prevalence in US youth and adults by sex
and age, 2007-2008 to 2015-2016. JAMA 2018;319:1723-5.
18. Félix-Redondo FJ, Grau M, Fernández-Bergés D. Cholesterol and cardiovascular disease in the elderly. Facts and Gaps. Aging Dis
2013;4:154-69.
19. Geiss LS, Wang J, Cheng YJ, Thompson TJ, Barker L, et al. Prevalence and incidence trends for diagnosed diabetes among adults aged 20
to 79 years, united states, 1980-2012. JAMA 2014;312:1218-26.
20. Akram M. Mini-review on glycolysis and cancer. J Cancer Educ 2013;28:454-7.
21. Wu C, Khan SA, Lange AJ. Regulation of glycolysis-role of insulin. Exp Gerontol 2005;40:894-9.
22. Moran LA, Horton HR, Scrimgeour KG, Perry MD. Principles of biochemistry. Available from: https://www.twirpx.com/file/718377/. [Last
accessed on 27 Mar 2019]
23. Champe PC, Harvey RA, Ferrier DR. Lippincott's illustrated reviews: biochemistry. Philadelphia: Wolters Kluwer/Lippincott Williams &
Wilkins; 2008.
24. Potter M, Newport E, Morten KJ. The Warburg effect: 80 years on. Biochemical Society Transactions 2016;44:1499-505.
25. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine
metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007;104:19345-50.
26. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation.
Science 2009;324:1029-33.
27. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927;8:519-30.
28. Warburg O. The chemical constitution of respiration ferment. Science 1928;68:437-43.
29. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
30. Bischoff R, Schlüter H. Amino acids: chemistry, functionality and selected non-enzymatic post-translational modifications. J Proteomics
2012;75:2275-96.
31. Kanarek N, Keys HR, Cantor JR, Lewis CA, Chan SH, et al. Histidine catabolism is a major determinant of methotrexate sensitivity. Nature
2018;559:632-6.
32. Hopkins BD, Pauli C, Du X, Wang DG, Li X, et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature
2018;560:499-503.
33. Maddocks ODK, Athineos D, Cheung EC, Lee P, Zhang T, et al. Corrigendum: modulating the therapeutic response of tumours to dietary
serine and glycine starvation. Nature 2017;548:122.
34. Steiner N, Muller U, Hajek R, Sevcikova S, Borjan B, et al. The metabolomic plasma profile of myeloma patients is considerably different
from healthy subjects and reveals potential new therapeutic targets. PLoS One 2018;13:e0202045.
35. Puchades-Carrasco L, Lecumberri R, Martinez-Lopez J, Lahuerta JJ, Mateos MV, et al. Multiple myeloma patients have a specific serum
metabolomic profile that changes after achieving complete remission. Clin Cancer Res 2013;19:4770-9.
36. Ludwig C, Williams DS, Bartlett DB, Essex SJ, McNee G, et al. Alterations in bone marrow metabolism are an early and consistent feature
during the development of MGUS and multiple myeloma. Blood Cancer J 2015;5:e359.
37. Gonsalves WI, Ramakrishnan V, Hitosugi T, Ghosh T, Jevremovic D, et al. Glutamine-derived 2-hydroxyglutarate is associated with disease
progression in plasma cell malignancies. JCI Insight 2018;3:94543.
38. Hossen MA, Nagata Y, Waki M, Ide Y, Takei S, et al. Decreased level of phosphatidylcholine (16:0/20:4) in multiple myeloma cells
compared to plasma cells: a single-cell MALDI-IMS approach. Anal Bioanal Chem 2015;407:5273-80.
39. Zub KA, Sousa MM, Sarno A, Sharma A, Demirovic A, et al. Modulation of cell metabolic pathways and oxidative stress signaling